Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CALCA | P06881 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | BRD2 | P25440 | 1/20 | 0.36 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.36 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4399670 | 0.86 | SCD (0.43) | EGLN1CYP2C9LMNACALCAKCNH2 | |
| SCHEMBL5537848 | 0.85 | CYP2C9 (0.41) | CYP2C9P2RX7KCNH2 | |
| SCHEMBL5538731 | 0.85 | KCNH2 (0.46) | EGLN1CYP2C9LMNAKCNH2SCD | |
| SCHEMBL5534072 | 0.81 | MMP13 (0.42) | EGLN1CYP2C9CALCAKCNH2SCD | |
| SCHEMBL4397947 | 0.81 | CYP2C9 (0.39) | CYP2C9P2RX7CALCAKCNH2SCD | |
| SCHEMBL4396394 | 0.79 | CYP2C9 (0.42) | CYP2C9P2RX7CALCAKCNH2 | |
| SCHEMBL5643962 | 0.79 | MAPT (0.37) | P2RX7LMNA | |
| SCHEMBL5542241 | 0.79 | CYP2C9 (0.42) | CYP2C9P2RX7KCNH2 | |
| SCHEMBL4393763 | 0.77 | CYP2C9 (0.40) | CYP2C9KCNH2 | |
| SCHEMBL5532945 | 0.77 | GAA (0.48) | CYP2C9LMNAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050267132-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | claimed |
| US-7192948-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192948-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192948-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1753767-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005118589-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050267132-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267132-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TOP1, APOBEC3C | EGLN1 768/4885CYP2C9 237/4885P2RX7 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.